PFAS Treatment Moves Into Regulated Water Delivery

By OFW Intelligence Editorial · 2026-08-18

This analysis draws on research from the Our Future Water Intelligence report Ofwat’s £3.4 Billion Growth and Water-Quality Package: Capacity, PFAS, Data Centres, and Bill Risk.

PFAS treatment is becoming an execution issue for regulated water companies rather than a distant monitoring concern. Once a scheme enters a price-control decision, technology selection, evidence quality, procurement readiness, and long-term operating responsibility become inseparable parts of the same delivery case. That transition places delivery governance alongside contaminant science at the centre of investment decisions.

The treatment challenge is not solved by naming a preferred process. Utilities must understand source-water conditions, contaminant profiles, media performance, waste handling, maintenance needs, and the way a new process will integrate with existing works without weakening reliability. Each interface needs an accountable owner and a documented performance rationale.

Granular activated carbon can provide a practical treatment route, but its value depends on site-specific design and disciplined operation. Bed configuration, change-out strategy, monitoring, and residual management all influence whether compliance is sustained rather than achieved only at commissioning. Lifecycle assumptions should be tested under realistic loading and operational variability.

Alternative treatment options may also have a role where water chemistry, footprint, or operational constraints differ. The investment case should therefore show why the selected approach represents the best available option for the site, not merely that the technology can remove the target substances. Option appraisal should remain open until the evidence supports a defensible site solution.

Regulatory evidence gates can improve that decision by forcing scope and cost assumptions into the open. Clear option appraisal, design maturity, supplier input, and delivery sequencing help distinguish a credible treatment programme from an early estimate that still carries material uncertainty. The resulting record gives regulators and customers a clearer view of value.

Procurement strategy matters because specialist treatment markets can tighten as more jurisdictions respond to persistent contaminants. Utilities that coordinate specifications, qualification, media supply, installation, and assurance can reduce interface risk without treating vendor availability as a substitute for technical diligence. Framework agreements can support resilience, but they must preserve site-specific performance tests.

Operating teams need to be involved before equipment choices are fixed. Their knowledge of flows, shutdown windows, laboratory capability, maintenance access, and process interactions can prevent a compliance project from introducing avoidable reliability problems elsewhere in the works. Early involvement also improves commissioning plans and the transfer of knowledge to operations.

Monitoring capability is equally important because treatment performance must be demonstrated over time. Sampling plans, analytical methods, data governance, and escalation procedures should connect regulatory compliance with operational decisions on media replacement and process adjustment. Data quality becomes part of treatment control, not merely a compliance reporting function.

The waste pathway deserves the same scrutiny as the treatment train. Removing PFAS from water transfers the contaminants into spent media or other residuals, so procurement and operating plans must address handling, transport, regeneration, destruction, and evidentiary custody. A complete custody trail protects both environmental integrity and regulatory credibility.

Price control deliverables can translate these technical requirements into accountable outputs. A well-designed control should recognise the need for construction while also requiring evidence that the commissioned system performs as intended and supports the drinking-water obligation it was funded to meet. This keeps the control focused on water-quality outcomes rather than asset installation alone.

For investors and consumer representatives, that outcome focus is essential. Capital expenditure may create an asset, but regulatory value depends on whether the asset reduces compliance risk, operates reliably, and avoids future costs caused by incomplete design or weak residual management. Lifecycle transparency also helps distinguish prudent expenditure from avoidable remediation.

Supplier opportunity extends beyond media and vessels. Engineering integration, digital monitoring, laboratory services, performance verification, residual treatment, and independent assurance can all become part of a credible PFAS delivery chain. Capability providers will be judged on integration and evidence as well as technical supply.

The wider industry implication is a shift from contaminant surveillance toward repeatable treatment governance. Utilities will need stronger links between science, capital planning, procurement, operations, and regulatory reporting as persistent substances become embedded in mainstream investment programmes. This institutional integration is likely to shape procurement and workforce priorities.

That shift also raises the value of comparable performance evidence. Careful documentation of option choice, operating experience, and assurance can help later projects avoid duplicated learning while preserving the site-specific judgment needed for safe drinking-water treatment. Shared learning works best when methods, limits, and site context remain explicit.